GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Takara Bio Inc (TSE:4974) » Definitions » Cyclically Adjusted PB Ratio

Takara Bio (TSE:4974) Cyclically Adjusted PB Ratio : 1.58 (As of Jun. 04, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Takara Bio Cyclically Adjusted PB Ratio?

As of today (2024-06-04), Takara Bio's current share price is 円1034.00. Takara Bio's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was 円652.52. Takara Bio's Cyclically Adjusted PB Ratio for today is 1.58.

The historical rank and industry rank for Takara Bio's Cyclically Adjusted PB Ratio or its related term are showing as below:

TSE:4974' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.47   Med: 4.8   Max: 7.34
Current: 1.57

During the past years, Takara Bio's highest Cyclically Adjusted PB Ratio was 7.34. The lowest was 1.47. And the median was 4.80.

TSE:4974's Cyclically Adjusted PB Ratio is ranked better than
52.29% of 656 companies
in the Biotechnology industry
Industry Median: 1.745 vs TSE:4974: 1.57

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Takara Bio's adjusted book value per share data for the three months ended in Mar. 2024 was 円925.982. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is 円652.52 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Takara Bio Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Takara Bio's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takara Bio Cyclically Adjusted PB Ratio Chart

Takara Bio Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.85 6.17 4.27 2.92 1.49

Takara Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.92 2.70 2.21 1.96 1.49

Competitive Comparison of Takara Bio's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Takara Bio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Takara Bio's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Takara Bio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Takara Bio's Cyclically Adjusted PB Ratio falls into.



Takara Bio Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Takara Bio's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1034.00/652.52
=1.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takara Bio's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Takara Bio's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=925.982/107.2000*107.2000
=925.982

Current CPI (Mar. 2024) = 107.2000.

Takara Bio Quarterly Data

Book Value per Share CPI Adj_Book
201406 468.700 98.000 512.700
201409 470.344 98.500 511.887
201412 475.518 97.900 520.690
201503 494.444 97.900 541.414
201506 491.463 98.400 535.415
201509 495.898 98.500 539.698
201512 494.826 98.100 540.727
201603 498.314 97.900 545.651
201606 489.868 98.100 535.309
201609 479.097 98.000 524.073
201612 484.412 98.400 527.733
201703 497.301 98.100 543.432
201706 487.037 98.500 530.054
201709 490.284 98.800 531.968
201712 500.050 99.400 539.289
201803 513.636 99.200 555.058
201806 505.066 99.200 545.797
201809 516.294 99.900 554.021
201812 523.950 99.700 563.364
201903 531.557 99.700 571.544
201906 540.294 99.800 580.356
201909 535.377 100.100 573.351
201912 538.101 100.500 573.974
202003 552.202 100.300 590.190
202006 543.806 99.900 583.544
202009 557.484 99.900 598.221
202012 585.105 99.300 631.654
202103 616.031 99.900 661.046
202106 667.984 99.500 719.677
202109 702.490 100.100 752.317
202112 741.330 100.100 793.912
202203 796.165 101.100 844.203
202206 815.440 101.800 858.695
202209 886.053 103.100 921.289
202212 950.422 104.100 978.725
202303 931.911 104.400 956.905
202306 896.509 105.200 913.553
202309 928.896 106.200 937.643
202312 932.102 106.800 935.593
202403 925.982 107.200 925.982

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Takara Bio  (TSE:4974) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Takara Bio Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Takara Bio's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Takara Bio (TSE:4974) Business Description

Industry
Traded in Other Exchanges
Address
Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.

Takara Bio (TSE:4974) Headlines

No Headlines